Zobrazeno 1 - 10
of 115
pro vyhledávání: '"анализ затраты-эффективность"'
Autor:
Yu. A. Zabolotneva, I. S. Krysanov
Publikováno v:
Качественная клиническая практика, Vol 0, Iss 4, Pp 40-51 (2024)
Purpose of the study. Conducting an assessment of the economic consequences (clinical and economic analysis) when conducting cytogenetic studies before prescribing various first-line treatment regimens for multiple myeloma (MM). Materialsand methods.
Externí odkaz:
https://doaj.org/article/0439bbc4b0f04695b2c20a66bd0bdf14
Autor:
V. V. Omelyanovskiy, V. K. Fediaeva
Publikováno v:
Качественная клиническая практика, Vol 0, Iss 4, Pp 25-39 (2024)
Background. Health Technology Assessment (HTA) in the Russian Federation has been performed for drugs, not for other medical technologies, which leads to decision making difficulties today. Aim. This study aimed to assess the clinical and economic ef
Externí odkaz:
https://doaj.org/article/edf4819de846424db0cb7271eaf0cec6
Publikováno v:
Качественная клиническая практика, Vol 0, Iss 5, Pp 50-63 (2021)
Ipragliflozin is a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor that reduce plasma glucose concentrations by inhibiting glucose reabsorption by the kidney through inhibiting SGLT2 sodium-glucose cotransporter and induce glycosuria. SGLT
Externí odkaz:
https://doaj.org/article/3326312b1b5c4b98a97d9ae02c8e1e68
Publikováno v:
Качественная клиническая практика, Vol 0, Iss 3, Pp 40-51 (2020)
Aim. To assess the pharmacoeconomic feasibility of including the drug upadacitinib in restrictive lists and government funding programs to provide patients with rheumatoid arthritis.Materials and methods. Study Design — Retrospective Analysisof Lit
Externí odkaz:
https://doaj.org/article/6730714bb93a47e5aba8f30767e5f092
Publikováno v:
Качественная клиническая практика, Vol 0, Iss 1, Pp 4-21 (2020)
Objective. To determine the pharmacoeconomical feasibility of using a combination of atezolizumab + nab-paclitaxel in the 1st line of therapy for locally advanced or metastatic triple negative breast cancer (TNBC) in adult PDL1 positive patients in t
Externí odkaz:
https://doaj.org/article/547b6835489f46afa9c36e6ec461c397
Publikováno v:
Качественная клиническая практика, Vol 0, Iss 2, Pp 55-68 (2019)
Objective. To perform the pharmacoeconomic analysis of ceftolosan + tazobactam (Zerbaxa®) compared with the routine practice of antibacterial therapy of complicated intra-abdominal infections (clAI) and ceftazidime + avibactam (Zavicefta®).Methods.
Externí odkaz:
https://doaj.org/article/91c549683a7e4ed7b8a517ecc5d8ce6b
Publikováno v:
Качественная клиническая практика, Vol 0, Iss 1, Pp 27-52 (2019)
The aim. Based on a pharmacoeconomic analysis (PHe) of the use of sodium-glucose cotransporter-2 inhibitors (iSGLT2) and dipeptidyl peptidase-4 (iDPP-4) inhibitors to determine the optimal treatment strategy in patients with type 2 diabetes mellitus
Externí odkaz:
https://doaj.org/article/72c15650399c4fb8819759b378de1f25
Publikováno v:
Качественная клиническая практика, Vol 0, Iss 4, Pp 14-24 (2019)
Actuality. A major problem for rehabilitating patients after a stroke, other major cerebrovascular events or trauma (such as traumatic brain injury (TBI)) is increased muscle tone (spasticity) which in turn causes impairments of mobility and formatio
Externí odkaz:
https://doaj.org/article/a40878daa3934c5da9379eb838899994
Publikováno v:
Качественная клиническая практика, Vol 0, Iss 4, Pp 25-32 (2019)
Introduction. Regardless the pharmacoeconomic evaluation of trastuzumab emtanzine (T-DM-1) has been done before new data concerning T-DM1 effectiveness and also costs data require an update of pharmacoeconomic evaluation. Aim. To update pharmacoecono
Externí odkaz:
https://doaj.org/article/a7d431101f2f4a82baca414205d7acd9
Autor:
Y. M. Gomon, A. S. Kolbin, J. E. Balykina, M. A. Arepeva, S. V. Sidorenko, V. V. Strizheletskii, I. G. Ivanov
Publikováno v:
Качественная клиническая практика, Vol 0, Iss 3, Pp 14-25 (2019)
Introduction. Despite the high level of resistance of E.coli as the main causative agent of urinary tract infections, fluoroquinolones are among the most frequently used antimicrobial agents in empirical therapy of uroinfections.Aim. Clinical and ec
Externí odkaz:
https://doaj.org/article/afe1be09fd6d41aa901136f1c5d91a9e